Piper Jaffray analyst Matt Miksic reiterated an Overweight and 'Top Pick' rating and boosted his price target on Globus Medical (NYSE: GMED) to $28.00 (from $26.00) saying the current valuation as among the most compelling in their universe. Miksic said .. ...

20 people liked this